Healthcare Industry Visceral Pain Market Size and Forecast | Page 2

Your CatalystTo a Lucrative Business
In 2016, Crohn’s disease was the largest indication segment for the visceral pain market contributing to 41.4%
of the market share. Increasing occurrences of Crohn’s disease across the globe coupled with the growing drug
therapies for the treatment of the disease are the key factors attributing to the major share. Furthermore,
increasing awareness about Crohn’s disease is fueling the demand for treatment therapies.
Key market players include Pfizer, Johnson & Johnson, Abbvie, Takeda, Allergan, and AstraZeneca. These
companies are focusing on R&D for visceral pain therapeutics. These companies are likely to cater their
products to patients affected by visceral pain. The growth of the geriatric population is expected to help in
augmenting the profits of these companies over the next few years.
Growing focus on research and development by pharmaceutical companies and government initiatives are
expected to boost the visceral pain industry during the forecast period. The market is projected to witness
significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies.
Also, factors such as increasing awareness among people regarding visceral pain are further anticipated to
propel the market growth.
Hexa Research has segmented the global visceral pain market on the basis of therapeutics, indications and
region:
Segmentation by therapeutics, 2014 - 2024 (USD Million)
• Analgesics
• Narcotics
• NSAID
• Pain modifiers
• Tricyclic Antidepressants
• Tricyclic Anticonvulsant
• Others
Segmentation by indications, 2014 - 2024 (USD Million)
• Interstitial cystitis
• Crohn’s
• Irritable bowel
• Chronic prostatitis
Segmentation by region, 2014 - 2024 (USD Million)
• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)
Key players analyzed:
• Pfizer Inc.
• Allergan
• Johnson & Johnson
• Bayer AG
• Takeda Pharmaceutical Company Limited
Follow Us: